The next-generation Open Targets Platform: reimagined, redesigned, rebuilt

David Ochoa(European Bioinformatics Institute), Andrew Hercules(European Bioinformatics Institute), Miguel Carmona(European Bioinformatics Institute), Dániel Süveges(European Bioinformatics Institute), Jarrod Baker(European Bioinformatics Institute), Claudio Malangone(European Bioinformatics Institute), Irene López(European Bioinformatics Institute), Alfredo Miranda(European Bioinformatics Institute), Carlos Cruz-Castillo(European Bioinformatics Institute), Luca Fumis(European Bioinformatics Institute), Manuel Bernal Llinares(European Bioinformatics Institute), Kirill Tsukanov(European Bioinformatics Institute), Helena Cornu(European Bioinformatics Institute), Konstantinos D. Tsirigos(European Bioinformatics Institute), Olesya Razuvayevskaya(European Bioinformatics Institute), Annalisa Buniello(European Bioinformatics Institute), Jeremy Schwartzentruber(Wellcome Sanger Institute), Mohd Anisul Karim(Wellcome Sanger Institute), Bruno Ariano(Wellcome Sanger Institute), Ricardo Esteban Martinez Osorio(European Bioinformatics Institute), Javier Ferrer(European Bioinformatics Institute), Xiangyu Ge(Wellcome Sanger Institute), Sandra Machlitt‐Northen(GlaxoSmithKline (United Kingdom)), Asier Gonzalez‐Uriarte(European Bioinformatics Institute), Shyamasree Saha(European Bioinformatics Institute), Santosh Tirunagari(European Bioinformatics Institute), Chintan Mehta(European Bioinformatics Institute), Juan María Roldán‐Romero(European Bioinformatics Institute), Stuart Horswell(Wellcome Sanger Institute), Sarah Young(Wellcome Sanger Institute), Maya Ghoussaini(Wellcome Sanger Institute), David G. Hulcoop(GlaxoSmithKline (United Kingdom)), Ian Dunham(European Bioinformatics Institute), Ellen M. McDonagh(European Bioinformatics Institute)
Nucleic Acids Research
November 18, 2022
Cited by 434Open Access
Full Text

Abstract

The Open Targets Platform (https://platform.opentargets.org/) is an open source resource to systematically assist drug target identification and prioritisation using publicly available data. Since our last update, we have reimagined, redesigned, and rebuilt the Platform in order to streamline data integration and harmonisation, expand the ways in which users can explore the data, and improve the user experience. The gene-disease causal evidence has been enhanced and expanded to better capture disease causality across rare, common, and somatic diseases. For target and drug annotations, we have incorporated new features that help assess target safety and tractability, including genetic constraint, PROTACtability assessments, and AlphaFold structure predictions. We have also introduced new machine learning applications for knowledge extraction from the published literature, clinical trial information, and drug labels. The new technologies and frameworks introduced since the last update will ease the introduction of new features and the creation of separate instances of the Platform adapted to user requirements. Our new Community forum, expanded training materials, and outreach programme support our users in a range of use cases.


Related Papers

No related papers found

Powered by citation graph analysis